Cancer Pain Management Market, [by Pain Type (Acute Pain, Chronic Pain); by Drug Type (Opioid, Non-steroidal anti-inflammatory drug, Aspirin, Corticosteroids, Anti-depressants); by Treatment (Immunotherapy, Radiotherapy, Chemotherapy, Home therapy); by End Users (Hospitals, Cancer Care Clinics, Others)]; and Geography - Trend, Analysis and Forecast till 2025

The Global Cancer Pain Management Market Size is gaining traction owning to the factors such as ongoing research and development for developing new drugs, and rising number of patients suffering from cancer.

National Cancer Institute estimates approximately 5,80,350 Americans die from cancer. Cancer is the second leading cause of mortality in the U.S. which accounts for 1 in every 4 deaths. Pain is one of the most apprehended symptom in cancer. Despite greater availability of pain medications, it is often under-treated in the cancer patients. The pain observed due to growing tumour that destroys nearby tissues, press nerves, bones and organs. In some cases, the tumours cause pain as they release chemicals which harm the internal body parts. Cancer pain is a temporarily changing symptom that involves inflammatory, neuropathic, compression, and ischemic mechanisms. Cancer pain is categorized as chronic and acute pain which is distinct onset, and has prolonged effect. Chronic pain is also characterised by pain flares which is also termed as breakthrough pain.

Moreover, cancer pain is caused due to various cancer treatments procedures such as Surgical Pain, Phantom Pain, Procedure and Testing, and chemotherapy & radiation treatment. Cancer pain can be controlled by various pain relievers, like opioid, anti-inflammatory drugs, antidepressant, anti-seizers drugs and steroids.  

Increasing launch of new drug development as a novel treatment of cancer pain will drive growth in the cancer pain management market.

The cancer pain market is primarily driven by rising prevalence of cancer worldwide. According to WHO, cancer is the second leading cause of death in North America, and was responsible for 8.8 million deaths in 2015. Additionally, National Cancer Institute estimated 1,685,210 new cases in the U.S. suffering from cancer in 2016. Similarly, various ongoing technological advancements for reducing pain caused due to surgical process would also influence the growth of this market.  Moreover, the easy availability of the drugs that are used as painkiller would also propel the cancer pain management market.

However, side effects associated with the use of drugs that are used as a preferred treatment for cancer pain, and lack of awareness for using new technology for the pain treatment can hinder the market growth.

Global Cancer Pain Management Market Taxonomy

The cancer pain market is segmented on the basis of pain, drugs, route, treatment, and geography.

On the basis of pain type, global cancer pain management market size is segmented as;

• Acute Pain
• Chronic Pain

On the basis of drug type, global cancer pain management market share is segmented as;

• Opioid
• Non-steroidal anti-inflammatory drug
• Aspirin
• Corticosteroids
• Anti-depressants

On the basis of application type, global cancer pain management market size is segmented as;

• Immunotherapy
• Chemotherapy
• Radiotherapy
• Home Therapy

On the basis of end use type, global cancer pain management market share is segmented as;

• Hospitals
• Cancer Care Clinics
• Others

Geographically, the global cancer pain management market size is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

High number of leading manufacturers in North America to boost cancer pain management market in this region.

On the basis of geography, North America is expected to dominate the global cancer pain market share over forecast period. The primary factors influencing growth of cancer pain management market in this region are continuous efforts for new product development by the manufacturers, high number of patients suffering for cancer, and enhanced healthcare expenditure by the individuals and the government. While, Europe holds the second largest share in cancer pain management market owing to improved medical infrastructure for treating cancer pain. Also, there is a rising trend of consolidation between manufacturers for tapping this growing market.

Asia Pacific cancer pain management market is projected to witness lucrative market growth in the forecast period owning to the, increasing awareness for the use of various therapies as the treatment of cancer pain.

Key players in the global cancer pain management market are:

• Pfizer Inc.
• Mallinckrodt Pharmaceuticals
• Teva Pharmaceuticals
• Johnson & Johnson Inc.
• Endo Pharmaceuticals
• Eli Lilly & Company
• BioDelivery Sciences
• Prostrakan Group
• Sanofi S.A.
• Meda Pharmaceuticals
• Grunenthal Group
• Daiichi Sankyo